Evidence check: HLA-DQ2 in the context of blood sugar

HLA-DQ2 is a genetic marker strongly associated with celiac disease, an autoimmune condition triggered by gluten. There is no direct evidence linking HLA-DQ2 to blood sugar regulation. Celiac disease can indirectly affect blood glucose through malabsorption or associated autoimmunity (e.g., type 1 diabetes), but the variant itself does not modulate insulin or glucose metabolism. Evidence for a direct role in blood sugar control is weak and based on population associations, not causal pathways. MyBody-X tests for HLA-DQ2 are designed for celiac risk assessment, not glycemic management. For blood sugar insights, validated biomarkers like HbA1c, fasting glucose, or continuous glucose monitoring (CGM) are far more actionable. A DNA test alone cannot provide personalized carb intake recommendations. Caveat: Only about 30–40% of HLA-DQ2 carriers develop celiac disease; without symptoms or antibody testing, the predictive value is limited.